334 related articles for article (PubMed ID: 32721603)
1. Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper.
Al Salman J; Al Dabal L; Bassetti M; Alfouzan WA; Al Maslamani M; Alraddadi B; Elhoufi A; Enani M; Khamis FA; Mokkadas E; Romany I; Somily A; Kanj S
Int J Antimicrob Agents; 2020 Oct; 56(4):106104. PubMed ID: 32721603
[TBL] [Abstract][Full Text] [Related]
2. Infectious Complications in Severe Acute Pancreatitis: Pathogens, Drug Resistance, and Status of Nosocomial Infection in a University-Affiliated Teaching Hospital.
Tian H; Chen L; Wu X; Li F; Ma Y; Cai Y; Song S
Dig Dis Sci; 2020 Jul; 65(7):2079-2088. PubMed ID: 31691173
[TBL] [Abstract][Full Text] [Related]
3. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
5. High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region.
Vargas-Alzate CA; Higuita-Gutiérrez LF; López-López L; Cienfuegos-Gallet AV; Jiménez Quiceno JN
Int J Antimicrob Agents; 2018 Apr; 51(4):601-607. PubMed ID: 29277527
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Karlowsky JA; Hoban DJ; Hackel MA; Lob SH; Sahm DF
J Med Microbiol; 2017 Jan; 66(1):61-69. PubMed ID: 28051952
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
8. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study.
Motbainor H; Bereded F; Mulu W
BMC Infect Dis; 2020 Jan; 20(1):92. PubMed ID: 32000693
[TBL] [Abstract][Full Text] [Related]
9. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Biedenbach DJ; Giao PT; Hung Van P; Su Minh Tuyet N; Thi Thanh Nga T; Phuong DM; Vu Trung N; Badal RE
Clin Ther; 2016 Sep; 38(9):2098-105. PubMed ID: 27612610
[TBL] [Abstract][Full Text] [Related]
11. A prediction tool for nosocomial multi-drug Resistant Gram-Negative Bacilli infections in critically ill patients - prospective observational study.
Vasudevan A; Mukhopadhyay A; Li J; Yuen EG; Tambyah PA
BMC Infect Dis; 2014 Nov; 14():615. PubMed ID: 25420613
[TBL] [Abstract][Full Text] [Related]
12. EUropean prospective cohort study on
Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
[TBL] [Abstract][Full Text] [Related]
13. Changes in the incidence and antimicrobial susceptibility of healthcare-associated infections in a New York hospital system, 2006-2012.
Cohen B; Liu J; Larson E
J Prev Med Hyg; 2017 Dec; 58(4):E294-E301. PubMed ID: 29707660
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
15. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
Merz LR; Warren DK; Kollef MH; Fridkin SK; Fraser VJ
Chest; 2006 Dec; 130(6):1672-8. PubMed ID: 17166981
[TBL] [Abstract][Full Text] [Related]
16. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections.
Kunz AN; Brook I
Chemotherapy; 2010; 56(6):492-500. PubMed ID: 21099222
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological characteristics and antimicrobial susceptibility among carbapenem-resistant non-fermenting bacteria in Brazil.
Dias VC; Diniz CG; Peter AC; Bastos AN; Bastos VQ; Bastos LQ; Da Silva VL
J Infect Dev Ctries; 2016 Jun; 10(6):544-53. PubMed ID: 27367001
[TBL] [Abstract][Full Text] [Related]
18. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.
Hawkey PM; Warren RE; Livermore DM; McNulty CAM; Enoch DA; Otter JA; Wilson APR
J Antimicrob Chemother; 2018 Mar; 73(suppl_3):iii2-iii78. PubMed ID: 29514274
[TBL] [Abstract][Full Text] [Related]
19. Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).
Cantón R; Loza E; Aznar J; Castillo FJ; Cercenado E; Fraile-Ribot PA; González-Romo F; López-Hontangas JL; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
Rev Esp Quimioter; 2019 Apr; 32(2):145-155. PubMed ID: 30761824
[TBL] [Abstract][Full Text] [Related]
20. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
McGowan JE
Am J Med; 2006 Jun; 119(6 Suppl 1):S29-36; discussion S62-70. PubMed ID: 16735148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
